Tibolone and risk of gynecological hormone sensitive cancer
In conclusion, tibolone is associated with increased risk for ovarian and endometrial cancer overall; and particular the risk of serous ovarian tumors and Type 1 endometrial cancer. Because the associations are stronger with increasing durations of use ‐ and for hormone sensitive tumors ‐the results seem indicative of causality. This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Ellen Christine Leth L økkegaard, Lina Steinrud Mørch Tags: Research Article Source Type: research
More News: Cancer | Cancer & Oncology | Denmark Health | Endometrial Cancer | Hormonal Therapy | Hormones | Ovarian Cancer | Ovaries | Study | Women